The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

A biohacker who is 'reverse aging' has revealed the horrifying side-effect of a procedure to make him look younger.

The therapy, developed by PTC Therapeutics, is designed for patients across the severity of spectrum of AADC deficiency. It ...

This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...

The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...

A 29-year-old local patient is about to undergo a life-changing treatment that could dramatically alter the course of his ...

It is the first gene therapy directly administered to the brain and has received ... identifying centers of excellence and training surgeons for the procedure. The priority review voucher awarded to ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene ...

PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

The global cell and gene therapy market size was valued at USD 30.27 billion in 2024 and is projected to reach USD 190.82 ...

PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...